INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS
INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS
– Momentum Public Relations – June 13th, 2016
InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce today the addition of Dr. William J. Garner, M.D., to the Board of Directors. Dr. Garner is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, M&A or IPO transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as Chairman & Founder of Update Pharma and as a Director at IGXBio; previously serving as CEO of Invion Limited (ASX:IVX), a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded; and as a co-founder and Director of Del Mar Pharmaceuticals (OCTQX:DMPID). Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche’s oncology division. Prior to Roche, Dr. Garner was a healthcare merchant banker in New York City.
He has a Master of Public Health from Harvard and earned his M.D. at New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York.
“I am excited about joining InMed’s Board,” stated Dr. Garner. “In my review of the drug development programs, which involve topical administration with an inherently reduced risk of systemic toxicity, it became clear that InMed has the potential to achieve important, value-driving milestones in diseases with high unmet medical needs. The ultra-orphan lead indication is a particularly attractive opportunity, in my opinion. Together with the Directors and Management of the Company, I believe my skill sets can augment InMed’s efforts to optimize the development pathway and monetize its many assets.”
InMed also announces it has accepted the resignation of Steve Tong as a Director of the Company, effective today. The Board wishes to thank Mr. Tong for his efforts on behalf of the Company.
About InMed
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics drug candidate identification platform, biosynthesis manufacturing, and accelerated drug development pathway are the fundamental value drivers of the company.
- Published in InMed Pharmaceuticals, Life Sciences, News Home
InMed (IN:CSE) Updates Progress of its Epidermolysis Bullosa Program
InMed Updates Progress of its Epidermolysis Bullosa Program
– Momentum Public Relations – May 18th, 2016
InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies is pleased to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that has been specifically designed to: (i) modify the underlying cause of the disease in patients with epidermolysis bullosa simplex (EBS, the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed is now pleased to report that INM-750 has demonstrated positive pain relieving effects in animal models. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “I am very excited with these results as pain is a serious complication in EB and this animal data shows that INM-750 reduces both acute and chronic pain. Significant data has been previously generated and reported to demonstrate the diverse properties of INM-750 in wound healing, skin regeneration, anti-inflammation and its antibacterial effects. Together with pain, these disease hallmarks are key therapeutic targets for the effective treatment of EB as well as several other dermatological conditions.”
A summary of the pre-clinical results on INM-750, a non-THC cannabinoid based composition, is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in severe skin fragility that can range from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
- Published in InMed Pharmaceuticals, News Home
Medical Marijuana – 8 Uses of Cannabinoids
Medical Marijuana – 8 Uses of Cannabinoids
– Momentum Public Relations –
Canada has come a long way in regards to medical marijuana. It wasn’t that long ago that any mention of marijuana automatically conjured an image of a stereotypical stoner eating snacks on the couch. As the national conversation in Canada shifts towards the possibility of fully legalizing marijuana for adult users, many Canadians still have questions about medical marijuana and exactly what it is able to do. To answer those questions, we want to cover exactly what makes marijuana work as a form of medicine, as well as eight different medical use cases for marijuana:
Cannabinoids are the Key to Medical Marijuana
The reason marijuana can help people with different medical conditions is because it contains cannabinoids. The term cannabinoids refers to the active chemicals that are found in cannabis (marijuana). These chemicals are what causes the drug-like effects associated with marijuana usage. The two areas of the body that are most impacted by cannabinoids are the central nervous and immune systems.
Of the various cannabinoids found in marijuana, one of the most active and notable is delta-9-THC. More commonly identified simply as THC, this is the cannabinoid that’s responsible for the “high” associated with smoking marijuana. The other cannabinoid that’s important to note is cannabidiol (CBD). When isolated, CBD can lower inflammation or relieve pain without creating any of the effects associated with THC.
8 Medical Uses of Cannabinoids
The reason that Canadian companies like InMed Pharmaceuticals (IN:CSE) are investing so much R&D into drug discovery and development around cannabinoids is there are already numerous examples of their medical uses. Those uses include:
- Pain Management: Cannabinoids can be used to manage many different types of chronic pain. They are especially effective at managing pain that results from nerve damage. Cannabinoids make it possible for chronic pain sufferers to improve their quality of life without the risk of addiction and fatal overdose that opiates carry.
- Multiple Sclerosis: One of the effects of this condition is it causes painful muscle spasms. Individuals who have MS can use cannabinoids to help treat spasms and lessen their severity.
- Nausea: Individuals with AIDS and cancer patients are two examples of groups that struggle with significant nausea. Cannabinoids are very effective at lessening or completely stopping nausea in those types of people.
- Appetite Stimulant: In addition to significantly helping with nausea, cannabinoids are also an effective way to boost appetite. While lots of snacking is commonly portrayed in stereotypes of stoners, plenty of people with legitimate eating problems greatly benefit from this use of cannabinoids
- Epilepsy: Cannabinoids have been shown to dramatically reduce seizures in many people with epilepsy. For children with epilepsy and other patients, a cannabis oil that’s high in CBD and low in THC makes it possible to manage epilepsy without the typical side effects of feeling stoned.
- Crohn’s Disease: This disease causes bowel inflammation and commonly irritates the small intestine. Cannabinoids can lessen the need for someone with Crohn’s to take other types of medication. It can also reduce the likelihood of a person with Crohn’s Disease needing surgery.
- Cancer Treatment: Not only can cannabinoids help cancer patients manage their pain, but both THC and CBD have been shown to slow or even halt the growth of cancer cells.
- Parkinson’s Disease: Although studies have found that cannabinoids don’t help with the motor symptoms of this disease, cannabinoids have been shown to help reduce the tremors and stiffness associated with Parkinson’s.
While only time will tell whether or not marijuana will be legalized for all recreational users in Canada, there’s no doubt that significant progress will continue to be made within the realm of medical marijuana and using cannabinoids for therapeutic purposes.
- Published in Blog, InMed Pharmaceuticals, Life Sciences, Medical Marijuana
Cannabinoids – Investors See Green
Cannabinoids – Investors See Green
Momentum Public Relations
The current debate in Canada around legalizing or decriminalizing the use of marijuana is highlighting potential for mainstream investors to capitalize on opportunities being created by companies who are pioneers in developing medical products made from cannabis. The recent election of the Trudeau government has triggered anticipation that important reforms and regulatory changes will be introduced to fulfill promises that were included in the Liberal Party’s platform.
Scientists today have a better understanding of how the various molecules and compounds in cannabis trigger a response in human beings. This is permitting new classes of pharmaceutical products to emerge offering investors opportunities that eclipse the returns that can be generated in some of the more mature pharmaceutical segments.
InMed Pharmaceuticals (IN:CSE) http://www.inmedpharma.com is a leader in a growing segment that is seeking to identify new bioactive compounds in cannabis plants that may interact with certain genes that cause specific diseases or medical conditions. Their pioneering research is opening the door to new therapies that meet the needs of patients who suffer from a variety of illnesses including debilitating dermatological conditions and ocular nerve disorders like glaucoma. These new therapies are expected to generate substantial returns for investors.
Marijuana, in its many different forms, contains a variety of active ingredients. One of these ingredients, perhaps the most well known entity, is a cannabinoid known as tetrahydrocannabinol or THC. This is the primary psychoactive compound of cannabis. THC was first synthesized by Dr. R. Mechoulan at Jerusalem University in 1964. Since that time researchers have identified and isolated at least 85 different cannabinoids from cannabis, each with its own effects. Opportunities to investigate these effects and produce useful therapies is creating a potential pipeline of commercially viable pharmaceutical products as a result of the evolving public perception, advances in scientific knowledge and changes in laws and regulations
For most of the 20th century, marijuana was classified as an illegal drug in most jurisdictions in North America and Europe. It’s use, in a number of forms, was partially revived in the 1960’s as part of a counter cultural movement. Despite a well documented history of medical applications that date back to 2500 BC, the more recent mainstream public perception of cannabis was limited to publicity that highlighted the various negative consequences of smoking marijuana. This perspective, and the laws that were enacted that criminalized the possession of quantities of cannabis in any form, created an environment that impeded serious scientific investigation of its potential medicinal properties.
The use of cannabis in medicine is not a recent phenomenon. It actually pre-dates recorded history. There is clear evidence that a number of medicinal properties were well understood by Chinese emperors, Egyptian Pharaohs and Greek Philosophers. It was used by physicians in ancient times to treat ailments as diverse as glaucoma, gout, indigestion and anxiety. Eventually a debate about its use emerged among physicians. Around 900 AD two highly respected Islamic doctors had widely disparate opinions on the usefulness and efficacy of marijuana.
Eventually cannabis emerged in North America, primarily in the form of hemp. Two of the founding fathers of the United States of America, George Washington and Thomas Jefferson, both highly curious scientist-farmers, carefully documented experiments that they conducted in growing hemp and investigating a variety of medicinal uses for it.
At the beginning of the 20th century there was a movement to regulate and classify any product that made a medical claim. In 1906 President Teddy Roosevelt signed the Wiley Act into law. This legislation became the foundation for future food and drug related regulation. The objective of politicians and the medical community was to regulate or ban products that made health related claims but lacked any scientific credibility or were proven to be dangerous.
Marijuana, and its chemistry, was not well understood in that era and efforts were made to determine if it had helpful medicinal properties or if it was highly addictive. By the 1930’s there was considerable discussion around marijuana. In 1940 a committee of medical practitioners was established by the state of New York to study its use and effects. This was known as the “LaGuardia committee on the use of marihuana” (note the different spelling). The report that was produced in 1944 did not provide a clear recommendation on restricting its use. It did suggest that there was no evidence that that it was addictive or led to other more serious addictions.
“The practice of smoking marihuana does not lead to addiction in the medical sense of the word. The use of marihuana does not lead to morphine or heroin or cocaine addiction.” – LaGuardia committee report on the use of Marihuana (1944)
Nonetheless, the fact that cannabis was not treated as a legal compound led to an underground trade for recreational purposes. This discouraged investigation by medical researchers within the scientific community throughout most of the late 20th century. However, this is changing rapidly in the 21st century.
With accelerated scientific knowledge fueled by technology and communication, cannabinoid science is emerging into the mainstream. Scientists and medical professionals are already participating in trials that are being conducted to test new compounds from cannabinoids. Additional medical advances cannot be not far behind. Additionally, the anticipated change in the regulatory environment can only further fuel opportunities.
- Published in Blog, InMed Pharmaceuticals, Medical Marijuana
InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa
Vancouver, BC – November 04, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFNɣ/TNF⍺ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
CONTACT: Investors
Paul Brennan
President and Chief Executive Officer
Tel: 604.669.7207
Email: paul@inmedpharma.com
or
Chris Bogart
SVP, Corporate Strategy and Investor Relations
Tel: 604.669.7207
Email: chris@inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000
Vancouver, BC — November 2, 2015 – InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), is pleased to announce that it will conduct a non-brokered private placement of up to 6,666,667 units (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of up to C$1,000,000. Each Unit will consist of one common share and one of one non-transferable share purchase warrant. Each whole warrant will be exercisable by the holder to acquire one additional common share at a price of $0.30 for a period of twelve (12) months following the closing of the financing.
Completion of the private placement is subject to receipt of regulatory approval. All securities issued will be subject to a statutory four month hold period under applicable Securities Laws.
The net proceeds from this private placement will be used for general working capital purposes. Finders’ fees in cash or warrants may be payable in accordance with the policies of the Exchange.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Paul Brennan
President and Chief Executive Officer
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals
InMed Appoints Paul Brennan as President & Chief Executive Officer
Vancouver, BC — September 03, 2015 – InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today, that Paul Brennan, a 25-year veteran of the life sciences industry has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
Craig Schneider, Director, states, “We are extremely pleased that at this critical stage in the Company’s development, Mr. Brennan will be taking the helm of InMed and leading the Company through to its next clinical trials, financings and infrastructure buildout. Paul has extensive M&A, general management, financial, corporate and drug development expertise. We are fortunate to be under the leadership of an executive with broad global pharmaceutical development and commercialization experience with a proven track record of successfully bringing life science products to market on a global scale. We are pleased to bring his experience to bear on InMed’s operations as we make progress toward delivering meaningful therapies to underserved markets.”
Mr. Brennan was previously Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals- NASDAQ). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“I am excited for this opportunity and am excited to lead our talented and dedicated team. InMed’s corporate strategy, strong pipeline and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians, and shareholders as we advance our products through the clinic and into the market to deliver innovative and efficacious products.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com
Contact: InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
E: craig@inmedpharma.com
Investors:
Chris Bogart
SVP, Corporate Strategy and Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about Mr. Brennan acting as President and CEO of the Company; Mr. Schneider remaining on the board of directors; and the fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Mr. Brennan’s continued ability to serve as President and CEO; Mr. Schneider’s continued ability to serve as a director; continued demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the possibility that Mr. Brennan will no longer be willing or able to serve as President and CEO; the possibility that Mr. Schneider will no longer be willing or able to serve as a director; InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value; and economic or market conditions may worsen.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals